title: Pyoderma gangrenosum in a patient with primary cutaneous peripheral T-cell lymphoma, not otherwise specified.
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Patsatsi
authors.forename: Triantafyllia
authors.initials: T
authors.lastname: Koletsa
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Sotiriadis
authors.forename: Charalambos
authors.initials: C
authors.lastname: Kartsios
authors.forename: Antonios
authors.initials: A
authors.lastname: Papaconstantinou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kostopoulos
mesh_terms: D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D014750:Vincristine; D004317:Doxorubicin; D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone